Unique Technology Platform for Protein
Biomarker Discovery and Quantitation
Download a written
summary describing
our services. The written summary also shows an example of a
recent study.
Tissue proteomics requires a unique blend of competencies, from
pathology, histology and cell biology to mass spectrometry and
bioinformatics. With our expertise, we can offer comprehensive
biomarker discovery and validation services, as well as absolute
quantitation of protein biomarkers in tissue. Let us help you
with your projects from tissue sourcing and selection, through
sample processing, analysis and bioinformatics.
Expression Pathology’s proprietary Liquid Tissue® sample
processing and Director™ laser microdissection technologies
make possible —for the first time—mass spectrometry
based proteomic analysis of formalin-fixed paraffin-embedded
(FFPE) tissue.
Countless collections of formalin-fixed paraffin-embedded tissue
constitute a rich untapped source of protein information. Annotated
with detailed clinical outcome data, such as disease progression,
drug response and toxicity, they offer enormous potential for
discovery and analysis of protein biomarkers and drug targets.
Tissue Sourcing
Many organizations have their own tissue collections, but even
the best collections can lack a particular type of sample to
ensure that a study is representative and complete. We can procure
tissue samples that may be required for a study, to complement
an existing collection, or for an independent study.
DIRECTOR™ Slide Laser Microdissection
Good data requires analysis of the proper cells. In tissue
proteomics that means focusing on only the specific cells of
interest. DIRECTOR™ slides and the Leica LMD6000™ microdissection
system quickly and precisely harvest sufficient target cells
from even the most difficult and dispersed tissue features.
Liquid
Tissue® Sample Processing
The Liquid
Tissue® MS Protein Prep Kit provides a high
throughput, reproducible process for preparing FFPE tissue for
microproteomic mass spectrometry analysis. Our sample preparation
protocols use very small amounts of starting material.
•
Requires only 30,000 cells, the equivalent of an area 2 mm x
4 mm from a 10 µm thick tissue section.
• Enables analysis of microdissected cellular features
and conserves rare and precious tissue samples.
• Fully solubilizes all of the tissue sample, capturing the entire
protein content for mass spectrometry.
Mass Spectrometry Analysis
Through our alliances with leaders in proteomic mass spectrometry,
we provide a full range of state-of-the-art mass spectrometry
capabilities.
•
Global proteomic profiling using LC-MS/MS to identify
novel, differentially expressing candidate biomarkers
•
Protein Quantitation: When antibodies fail, or the
precision and accuracy of immunohistochemistry is insufficient,
we develop and validate protocols for absolute quantitation
of proteins in FFPE tissue using Single Reaction or Multiple
Reaction Monitoring (SRM/MRM) assays.
NextGen
Sciences is a highly qualified mass
spec CRO with experience generating excellent LC
MS/MS results with Liquid Tissue preps in FFPE tissue. Inquire
for details as we are continuously improving our
methods
and expanding our network of collaborators.
Bioinformatics Analysis
With our bioinformatics analysis capability we sort through
and organize large sets of data. EPI’s data processing
resources allow us to select the most relevant differentially
expressing proteins.
Mass spectrometry data is analyzed to investigate the
nature and types of proteins found and to search
for protein differences and commonalities between the tissue
samples, and
identify candidate protein biomarkers.
Project
Proposals and Collaborations
Every project is unique. Contact us to discuss how
we can help in areas that complement your own internal
needs, resources and expertise.
All tissue analysis projects are developed in collaboration
with the principal investigators and customized to
meet the specific needs of a study. Contact us to
discuss your project.
We reserve the right to continuously improve the methods used.
Expression Pathology Inc. (EPI) is a leader in tissue
microproteomics. Our technologies make possible mass spec protein analysis
of formalin-fixed tissue, enabling discovery, validation
and routine
measurement of protein
biomarkers related to clinical outcomes. Our near-term
mission is to offer breakthrough research tools and
collaborations to improve drug
and diagnostic development and for basic research.
Our proprietary technologies also provide the foundation
for a whole new platform of tissue diagnostic
tests currently under development.
The Liquid
Tissue® MS protocol prepares FFPE samples
for mass spec analysis. Complete solubilization captures the entire protein
content. Mass spec friendly. Requires only 30,000 cells for multiple
mass spectrometry analyses.
The Director™ Laser Microdissection Slides
provide the fastest, easiest and most accurate way to collect specific
cellular features from tissue sections. Engineered for use with existing
Leica LMD and PALM Zeiss laser microdissection system.
news sidebar
News & Events
NextGen
Sciences and Expression Pathology to provide protein biomarker
discovery and measurement in tissue, June 30, 2008. (press
release)
Quantitative
Proteomic Analysis of Formalin Fixed Paraffin Embedded Oral HPV Lesions
from HIV Patients, The Open Proteomics Journal, 2008, 1, 40-45,
June 15, 2008. (abstract)
Two
of Expression Pathology's key patents have issued covering
its DIRECTOR™ Slide technology for improved tissue laser microdissection Gaithersburg,
MD. May 19, 2008: (press release).
Expression
Pathology Obtains SBIR to Identify Protein Biomarkers of Breast
Cancer
Metastasis, May 15, 2008 (press
release).
ASMS,
Denver, June 1-5. (link)
Booth 21. Register for our tissue proteomic luncheon
seminar on Wednesday, June 4.
American
Association of Cancer Research, San
Diego, April 12-16. (link)
Booth 2428. See three posters using our technology; discovery
of endometrial cancer markers (write-up),
metastasis marker in melanoma (abstract),
protein biomarkers relating to metastasis and disease progression
in lung cancer (abstract).
A Molecular Portrait of Head and Neck Cancer Progression,
Clin. Cancer Res., Feb. 15, 2008 (abstract)
Expression Pathology Aids Research in Identifying Biomarkers
of Lung Cancer Metastasis and Survival, Feb. 19, 2008 (article
and press release)
Expression Pathology Obtains Maryland Funding to Develop
Breast Cancer Test, Feb. 6, 2008(press
release)